
    
      An open-label randomized clinical trial will be performed. Eligible patients are females and
      males, between 14 and 65 years undergoing allo-HCT for treatment of Acute Leukemia (AML or
      ALL). Patients must have a matching related peripheral blood stem cell donor. Patients from
      or referred to the KFSH&RC for allogeneic transplant consideration will be offered the
      opportunity to participate in this trial.

      Treatment Description:

      Patients will be randomized on one of the arms; an intervention or a standard of care arm.
    
  